Bleeding and thrombotic complications are the main cause of morbidity and mortality in critically ill patients on the intensive care unit (ICU), receiving short-term percutaneous mechanical circulatory support (pMCS) by extracorporeal membrane oxygenation (ECMO), balloon pumps or microaxial flow pumps.

This is due to a bidirectional interplay of various factors influencing the hemostatic balance, including coagulopathy during critical illness, sepsis/inflammation, platelet consumption, hyperfibrinolysis, shear-induced acquired von Willebrand syndrome and direct contact pathway activation by the artificial surface of the pMCS device.

To prevent thrombotic complications and device-induced localized intravascular coagulopathy (LIC), anticoagulation is indicated.

Unfortunately, all currently available anticoagulants carry an increased bleeding risk, further jeopardizing patients’ outcomes.

Therefore, the search for safer anticoagulants continues: the holy grail for the treatment of patients on pMCS and by extension, all patients on anticoagulation is to prevent thrombosis without affecting hemostasis, thus lowering the bleeding risk.

Read More